We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

News

03 Sep 21
AC Immune CEO Andrea Pfeifer Receives First SEF.WomenAward for CEO of the Year
Attachments:
PDF Version
02 Sep 21
AC Immune to Participate in Upcoming Virtual Investor Conferences in September
Attachments:
PDF Version
31 Aug 21
AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease
Attachments:
PDF Version
04 Aug 21
AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Attachments:
PDF Version
29 Jul 21
AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021
Attachments:
PDF Version
27 Jul 21
AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH
Attachments:
PDF Version
25 Jun 21
AC Immune Holds its Annual General Meeting of Shareholders
Attachments:
PDF Version
02 Jun 21
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta
Attachments:
PDF Version
20 May 21
AC Immune to Highlight First-in-Class Alzheimer’s Disease Vaccine Programs at Upcoming Investor Conferences
Attachments:
PDF Version
17 May 21
AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update
Attachments:
PDF Version
28 Apr 21
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
Attachments:
AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update
31 Mar 21
AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors
Attachments:
PDF Version
31 Mar 21
AC Immune Hosts Investor Webinar Highlighting the Power of its Morphomer™ Platform to Enable Precision Medicine for Neurodegenerative Disease
Attachments:
PDF Version
26 Mar 21
AC Immune to Host Webinar Highlighting its Innovative Morphomer™ Technology Platform and Pipeline
Attachments:
PDF Version
23 Mar 21
AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook
Attachments:
PDF Version
16 Mar 21
AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine
Attachments:
PDF Version
09 Mar 21
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases
Attachments:
PDF Version
24 Feb 21
AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference
Attachments:
PDF Version
17 Feb 21
AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference
Attachments:
PDF Version
11 Feb 21
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study
Attachments:
PDF Version
08 Feb 21
AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease
Attachments:
PDF Version
29 Jan 21
AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway
Attachments:
PDF Version